Akari Therapeutics, Plc
AKTX · NASDAQ
Bulios Fair Price
$10.51
17.6% upside
Current Price
$8.94
According to Bulios Fair Price, AKTX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Akari Therapeutics, Plc (AKTX) is a biopharmaceutical company focused on developing therapies for the treatment of inflammatory diseases and autoimmune disorders. The company's main focus is on researching and developing complement inhibition-based therapies, which play a key role in the body's immune response. One of the company's main products is Nomacopan (also known as Coversin), which is being developed for the treatment of various diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and other autoimmune disorders. Akari Therapeutics, Plc aims to bring innovative therapeutic solutions to patients with diseases that have not been adequately addressed by existing treatments. Shares of Akari Therapeutics, Plc (AKTX) could be suitable for investors who are tracking the biotechnology sector and seeking opportunities in the development of drugs for inflammatory diseases and autoimmune disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
Abizer Gaslightwala
Employees
6
Headquarters
Tampa
Upcoming events
Earnings
Upcoming earnings report